Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
19 sept. 2024 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
28 août 2024 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
19 août 2024 07h00 HE
|
Supernus Pharmaceuticals, Inc.
PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Announces Second Quarter 2024 Financial Results
06 août 2024 16h06 HE
|
Supernus Pharmaceuticals, Inc.
Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01 août 2024 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
23 juil. 2024 16h13 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 mai 2024 16h25 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
23 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May ...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
09 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2024 Financial Results
08 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales...